Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) shares were up 2.1% during trading on Thursday . The stock traded as high as $3.96 and last traded at $3.94, with a volume of 989,450 shares changing hands. The stock had previously closed at $3.86.

Several research analysts have recently commented on SGYP shares. Rodman & Renshaw decreased their price target on shares of Synergy Pharmaceuticals from $16.00 to $15.00 and set a “buy” rating for the company in a report on Monday, May 9th. Roth Capital reaffirmed a “buy” rating and issued a $6.50 price target on shares of Synergy Pharmaceuticals in a report on Thursday, May 26th. Zacks Investment Research raised shares of Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Monday, May 16th. Canaccord Genuity reaffirmed a “buy” rating and issued a $13.00 price target on shares of Synergy Pharmaceuticals in a report on Monday, May 23rd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $11.00 price target on shares of Synergy Pharmaceuticals in a report on Tuesday, April 19th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $10.37.

The stock’s 50-day moving average price is $3.74 and its 200-day moving average price is $3.63. The stock’s market capitalization is $740.68 million.

Synergy Pharmaceuticals (NASDAQ:SGYP) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.28. On average, equities research analysts predict that Synergy Pharmaceuticals Inc. will post ($1.01) earnings per share for the current fiscal year.

Other institutional investors have made changes to their positions in the company. California State Teachers Retirement System boosted its position in shares of Synergy Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 185,372 shares of the biopharmaceutical company’s stock worth $1,051,000 after buying an additional 3,251 shares in the last quarter. Oxford Asset Management acquired a new position in shares of Synergy Pharmaceuticals during the fourth quarter worth about $1,102,000. Morgan Stanley boosted its position in shares of Synergy Pharmaceuticals by 6.8% in the fourth quarter. Morgan Stanley now owns 423,520 shares of the biopharmaceutical company’s stock worth $2,401,000 after buying an additional 27,037 shares in the last quarter. Finally, EAM Investors LLC acquired a new position in shares of Synergy Pharmaceuticals during the fourth quarter worth about $3,672,000.

Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.